1. Molecular and clinical characterization of H3 K27M-mutant 'non-midline' glioblastoma: A case report and literature review
- Author
-
Kazuhiko Sugiyama, Kazuya Kuraoka, Takashi Kurashige, Shinji Ohba, Fumiyuki Yamasaki, and Shumpei Onishi
- Subjects
Pathology ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Mutant ,General Medicine ,Fluid-attenuated inversion recovery ,medicine.disease ,Lesion ,Diffuse Glioma ,Glioma ,Biopsy ,Medicine ,Surgery ,Neurology (clinical) ,medicine.symptom ,business ,Pathological ,Glioblastoma - Abstract
The WHO classification of tumors of the CNS in 2016 defined “diffuse midline glioma, H3 K27M-mutant” as a new tumor entity locating in the CNS midline. However, the H3 K27M-mutation in “non-midline” glioblastoma are rare and their characteristics have been rarely reported. A 16-year-old girl presented a hyper-intense lesion at her left temporal stem on T2WI, FLAIR and DWI. Biopsy was performed and molecular pathological diagnosis was glioblastoma with H3 K27M-mutant. Accordingly, the possibility of H3 K27M-mutant should be examined not only for diffuse glioma without IDH mutation that develops at a midline location, but also in non-midline locations.
- Published
- 2022
- Full Text
- View/download PDF